SCHEMBL3203565

SCHEMBL3203565

CC(C)(C)OC(=O)N1CCC(c2c[nH]c3cccnc23)C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 3/20 0.49
HSD11B1 P28845 4/20 0.48
PDE10A Q9Y233 1/20 0.48
CCNK O75909 1/20 0.47
CDK12 Q9NYV4 1/20 0.47
GPR119 Q8TDV5 2/20 0.47
JAK2 O60674 2/20 0.46
JAK1 P23458 2/20 0.46
TYK2 P29597 1/20 0.46
JAK3 P52333 1/20 0.46
PARP1 P09874 2/20 0.44
PDE4B Q07343 1/20 0.44
HTR1A P08908 1/20 0.43
HTR1D P28221 1/20 0.43
HTR1B P28222 1/20 0.43
HTR1F P30939 1/20 0.43
CCR2 P41597 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31295138 1.00 HPGDS (0.49) HPGDSHSD11B1PDE10ACCNKCDK12
SCHEMBL31530773 0.99 HPGDS (0.48) HPGDSHSD11B1PDE10ACCNKCDK12
SCHEMBL2347633 0.94 PDE10A (0.54) HPGDSPDE10AGPR119JAK2JAK1
SCHEMBL21714498 0.86 PDE10A (0.44) HPGDSPDE10AGPR119JAK2JAK1
SCHEMBL22608960 0.84 HPGDS (0.50) HPGDSPDE10ACCNKCDK12JAK2
SCHEMBL3210431 0.83 HSD11B1 (0.50) HSD11B1HTR1AHTR1DHTR1BHTR1F
SCHEMBL3203060 0.83 HSD11B1 (0.50) HSD11B1HTR1AHTR1DHTR1BHTR1F
SCHEMBL12509445 0.83 HSD11B1 (0.69) HPGDSHSD11B1CCNKCDK12GPR119
SCHEMBL14181451 0.83 KDM4E (0.63) HPGDSHSD11B1JAK2JAK1PDE4B
SCHEMBL13532404 0.82 POLB (0.49) PDE10AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119698412-A 5-HT2A receptor agonist, and preparation method and application thereof 上海翊石医药科技有限公司 2025-03-25 CN disclosed
WO-2025021120-A1 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-01-30 WO disclosed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010011546-A2 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-28 WO disclosed
WO-2010011546-A2 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR1A, HTR5A HPGDS 1445/4885HSD11B1 2163/4885PDE10A 673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.